Table of contents
From the editors
p625 | doi:10.1038/nri1927
Research Highlights
Regulatory T cells: Perfect partnership | PDF (648 KB)
p626 | doi:10.1038/nri1929
Inflammation: Gouty inflammation crystal clear? | PDF (230 KB)
p627 | doi:10.1038/nri1923
In brief
Dendritic cells | Asthma and allergy | T-cell responses | PDF (65 KB)
p627 | doi:10.1038/nri1933
In the news
Allergy and Parkinson's disease | PDF (47 KB)
p628 | doi:10.1038/nri1926
T cells: Competing for dominance | PDF (120 KB)
p628 | doi:10.1038/nri1931
Signalling: Conjugating enzyme IDed | PDF (115 KB)
p629 | doi:10.1038/nri1930
In brief
Mast cells | Immunotherapy | HIV | PDF (63 KB)
p629 | doi:10.1038/nri1932
Natural killer cells: When killers come good | PDF (99 KB)
p630 | doi:10.1038/nri1922
Regulatory T cells: Suspended license to kill | PDF (97 KB)
p630 | doi:10.1038/nri1924
T-cell development: The missing link for T cells? | PDF (69 KB)
p631 | doi:10.1038/nri1921
Antibodies: Unmasking IgG responses | PDF (89 KB)
p632 | doi:10.1038/nri1925
Innate immunity: Pick a CARD | PDF (95 KB)
p632 | doi:10.1038/nri1928
Reviews
The role of heparan sulphate in inflammation
Christopher R. Parish
p633 | doi:10.1038/nri1918
The importance of heparan sulphate, which is ubiquitously expressed as a proteoglycan, in leukocyte extravasation is often overlooked. Owing to the remarkable structural diversity of heparan sulphate proteoglycans, these molecules interact specifically with numerous proteins and participate in almost all stages of leukocyte extravasation.
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors
Kenya Honda & Tadatsugu Taniguchi
p644 | doi:10.1038/nri1900
Members of the interferon-regulatory factor (IRF) family of transcription factors are known to have diverse immunoregulatory roles. This article reviews this rapidly developing field, describing how IRFs are the master regulators of immune responses mediated by both transmembrane and cytosolic pattern-recognition receptors.
Article series: Tumour immunology
Tumour–induced immune modulation of sentinel lymph nodes
Alistair J. Cochran, Rong-Rong Huang, Jonathan Lee, Eijun Itakura, Stanley P. L. Leong & Richard Essner
p659 | doi:10.1038/nri1919
The sentinel lymph node (SLN) is the first node to receive lymph from a primary tumour. In this Review, the immunology of the SLN, the way in which tumour cells modulate the SLN to facilitate metastases, and possible therapies to reverse this process are discussed.
Balancing co-stimulation and inhibition with BTLA and HVEM
Kenneth M. Murphy,
Christopher A. Nelson
&
John R. 
edý
p671 | doi:10.1038/nri1917
A discussion of structural and functional studies examining the unexpected interaction of the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) with the co-stimulatory receptor herpesvirus-entry mediator (HVEM) and their role in the regulation of many types of cell.
Tissue-tropic effector T cells: generation and targeting opportunities
William W. Agace
p682 | doi:10.1038/nri1869
To mediate their function, effector T cells must home to extralymphoid tissues. William Agace reviews how homing to certain tissues is bestowed on effector T-cell subsets and describes an important role for draining lymph nodes and tissue-derived dendritic cells in this process.
Perspectives
Opinion
Toll-like receptors as molecular switches
Nicholas J. Gay, Monique Gangloff & Alexander N. R. Weber
p693 | doi:10.1038/nri1916
How Toll-like receptors respond to specific ligands and activate selective signalling pathways is not fully understood. This Perspective proposes a molecular mechanism, involving a series of protein conformational changes that are initiated by receptor dimerization, that might account for this specificity.
Essay
Envisioning future strategies for vaccination against tuberculosis
Stefan H. E. Kaufmann
p699 | doi:10.1038/nri1920
Stefan Kaufmann looks to the future of vaccination against tuberculosis. By drawing on past and present vaccination approaches, he proposes that the most successful strategy for preventing tuberculosis in the future will combine different vaccine candidates and use a prime–boost approach.
